Cancer News
OncoLink Cancer News - HealthDay


Active surveillance in low-risk disease tied to 2.4 percent cancer-specific death rate over 10 years

-- Jeff Muise

Monday, June 21, 2010 (Last Updated: 06/22/2010)

MONDAY, June 21 (HealthDay News) -- For patients with prostate cancer that has a low risk of progression, active surveillance is associated with a low death rate, suggesting that it may be a sufficient management approach, according to research published online June 18 in the Journal of the National Cancer Institute.

Pär Stattin, M.D., of the Umeå University Hospital in Sweden, and colleagues extracted data from Sweden's National Prostate Cancer Registry 1997 to 2002 on 6,849 patients with localized prostate cancer, aged 70 years or younger, who had low to intermediate risk of progression and were managed using one of three approaches: active surveillance and watchful waiting, radical prostatectomy, or radiation therapy.

After 10 years of follow-up, the researchers found that cumulative prostate cancer-specific death rates overall were 2.4 percent for those in the prostatectomy group, 3.6 percent for those in the surveillance group, and 3.3 percent for those in the radiation-therapy group. For those with low-risk disease, the rates were 0.4, 2.4, and 1.8 percent, respectively. The 10-year risk of dying from competing causes, however, was 19.2 percent in the surveillance group, 8.5 percent in the prostatectomy group, and 14.2 percent in the radiation-therapy group.

"A 10-year prostate cancer-specific mortality of 2.4 percent among patients with low-risk prostate cancer in the surveillance group indicates that surveillance may be a suitable treatment option for many patients with low-risk disease," the authors write.

Abstract
Full Text
Editorial

Specialties Gastroenterology
Hematology & Oncology
Pathology
Radiology

Copyright © 2010 HealthDay. All rights reserved.


I Wish You Knew

Genomics & Cancer

View More



Blogs and Web Chats

OncoLink Blogs give our readers a chance to react to and comment on key cancer news topics and provides a forum for OncoLink Experts and readers to share opinions and learn from each other.




OncoLink OncoPilot

Facing a new cancer diagnosis or changing the course of your current treatment? Let our cancer nurses help you through!

Learn More